Opaleye Management reports acquisition of $158,600.8689 in Grace Therapeutics common shares
GRCE•Opaleye Management purchased 87,801 Grace Therapeutics common shares, bringing its indirect holdings to 3,036,411 shares. The purchases were made at $1.9258 and $1.7679 per share.
1. Share purchases
Opaleye Management, a 10% owner of Grace Therapeutics, purchased 87,801 common shares. The purchases included 21,390 shares at $1.9258 per share and 66,411 shares at $1.7679 per share, bringing indirect holdings to 3,036,411 shares.
